---
title: "Adagio Medical | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286096054.md"
datetime: "2026-05-12T12:07:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286096054.md)
  - [en](https://longbridge.com/en/news/286096054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286096054.md)
---

# Adagio Medical | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.31.

EBIT: As of FY2026 Q1, the actual value is USD -4.529 M.

#### Segment Revenue

Revenue was $0 for the three months ended March 31, 2026, which was consistent with the three months ended March 31, 2025 .

#### Operational Metrics

-   **Cost of Revenue**: Cost of revenue was $0 for the three months ended March 31, 2026, compared to $253 thousand for the three months ended March 31, 2025 . This decrease was primarily due to a pause in commercial activity in Europe .
-   **Research and Development Expenses**: Research and development expenses were $2,741 thousand for the three months ended March 31, 2026, a decrease from $3,659 thousand for the three months ended March 31, 2025 . This reduction was mainly attributable to lower clinical trial expenses and product development costs, partially offset by higher operational costs including depreciation expense .
-   **Selling, General and Administrative Expenses**: Selling, general and administrative expenses decreased to $2,459 thousand for the three months ended March 31, 2026, from $3,485 thousand for the three months ended March 31, 2025 . This decline was primarily due to lower professional services expenses, regulatory reporting expenses, and payroll and personnel expenses .
-   **Total Cost of Revenue and Operating Expenses**: Total cost of revenue and operating expenses was $5,200 thousand for the three months ended March 31, 2026, down from $7,397 thousand for the three months ended March 31, 2025 .
-   **Loss from Operations**: Loss from operations improved to - $5,200 thousand for the three months ended March 31, 2026, compared to - $7,397 thousand for the three months ended March 31, 2025 .
-   **Net Loss**: Net loss for the three months ended March 31, 2026, was - $6,995 thousand, an improvement from a net loss of - $7,713 thousand for the three months ended March 31, 2025 .

#### Cash and Balance Sheet Metrics

-   **Cash and Cash Equivalents**: Adagio Medical Holdings, Inc. reported cash and cash equivalents of $12.9 million as of March 31, 2026 .
-   **Total Assets**: Total assets were $39,308 thousand as of March 31, 2026, compared to $43,253 thousand as of December 31, 2025 .
-   **Total Liabilities**: Total liabilities were $33,583 thousand as of March 31, 2026, compared to $30,851 thousand as of December 31, 2025 .
-   **Total Stockholders’ Equity**: Total stockholders’ equity was $5,725 thousand as of March 31, 2026, compared to $12,402 thousand as of December 31, 2025 .

#### Unique Metrics

-   **Weighted-Average Shares Outstanding**: Weighted-average shares outstanding were 22,210,459 for the three months ended March 31, 2026, up from 15,375,521 for the three months ended March 31, 2025 .

#### Outlook / Guidance

Adagio Medical Holdings, Inc. anticipates achieving multiple additional meaningful milestones across its technology platform during the current year . The company expressed confidence in its mission to fundamentally change the treatment of ventricular tachycardia with a safe and effective solution for a broad patient population .

### Related Stocks

- [ADGM.US](https://longbridge.com/en/quote/ADGM.US.md)

## Related News & Research

- [Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress | ADGM Stock News](https://longbridge.com/en/news/286095782.md)
- [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md)
- [HPE to Present Live Audio Webcast of Fiscal 2026 Second Quarter Earnings Conference Call | HPE Stock News](https://longbridge.com/en/news/285935495.md)
- [Orrstown to present operating results at virtual annual shareholders meeting; presentation furnished on Form 8-K](https://longbridge.com/en/news/285202154.md)
- [Adagio Medical Announces Positive Pivotal FULCRUM-VT Results; 84% Shock-Free at 6 Months](https://longbridge.com/en/news/284193943.md)